09:23 AM EST - Oncolytics Biotech Inc : Announces ASCO Abstracts highlight Pelareorep's potential in pancreatic icancer and immunotherapeutic mechanism of action. Trial-in-progress abstract highlights new cohort that could expand the company's pancreatic cancer program. Pelareorep's ability to expand TILs highlights its immunotherapeutic mechanism of action and potential as a backbone immunotherapy for multiple indications. Oncolytics Biotech Inc
shares T.ONC are trading unchanged at $1.45.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=ONCY&qmodStoryID=7991081931685552
